Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.
Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.